23Apr/13

Federal Circuit finds prosecution history disclaimer in enablement arguments – Lexology (registration)

Federal Circuit finds prosecution history disclaimer in enablement arguments
Lexology (registration)
The specification describes Biogen’s product Rituxan® (rituximab) as a preferred embodiment. Rituximab binds to a large loop of the CD20 protein that is exposed on the cell surface. This loop constitutes the particular “epitope” recognized by the

23Apr/13

Integral Molecular Launches MPS Platform for Discovery of Antibodies Targeting … – PharmiWeb.com (press release)

Integral Molecular Launches MPS Platform for Discovery of Antibodies Targeting
PharmiWeb.com (press release)
MPSTM enables the isolation characterization and engineering of monoclonal antibodies (MAbs) against difficult membrane protein targets including GPCRs transporters and ion channels. The technology platform harnesses the strength of Integral’s

and more »

23Apr/13

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients … – News-Medical.net

Enrollment for Pharmacyclics’ Phase III study using ibrutinib in CLL patients
News-Medical.net
planned 110 patients in the Phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) who progress after bortezomib therapy and have received at least one prior rituximab-containing chemotherapy regimen, SPARK (MCL2001).

22Apr/13

Antibodies turn marrow cells into brain precurors – U-T San Diego


Science Codex

Antibodies turn marrow cells into brain precurors
U-T San Diego
LA JOLLA — Bone marrow cells can be directly converted into brain precursor cells with antibodies, according to scientists at The Scripps Research Institute. It opens an unexpected path to a more effective way of producing these cells. The precursor
Antibody transforms stem cells directly into brain cells – Science DailyScience Daily (press release)

all 3 news articles »

22Apr/13

Integral Molecular Launches MPS Platform for Discovery of Antibodies Targeting … – Business Wire (press release)

Integral Molecular Launches MPS Platform for Discovery of Antibodies Targeting
Business Wire (press release)
MPSTM enables the isolation, characterization, and engineering of monoclonal antibodies (MAbs) against difficult membrane protein targets including GPCRs, transporters and ion channels. The technology platform harnesses the strength of Integral’s

and more »